Home » Stocks » Curis, Inc.

Curis, Inc. (CRIS)

Stock Price: $1.28 USD 0.02 (1.59%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $1.29 +0.01 (0.78%) Aug 14, 7:52 PM

Stock Price Chart

Key Info

Market Cap 68.95M
Revenue (ttm) 11.21M
Net Income (ttm) -31.46M
Shares Out 53.87M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $1.28
Previous Close $1.26
Change ($) 0.02
Change (%) 1.59%
Day's Open 1.26
Day's Range 1.24 - 1.32
Day's Volume 870,605
52-Week Range 0.62 - 3.59

More Stats

Market Cap 68.95M
Enterprise Value 53.26M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 53.87M
Float 40.89M
EPS (basic) -0.9
EPS (diluted) -0.90
FCF / Share -0.71
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 692,179
Short Ratio 0.51
Short % of Float 1.27%
Beta 2.33
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.15
PB Ratio n/a
Revenue 11.21M
Operating Income -26.57M
Net Income -31.46M
Free Cash Flow -28.13M
Net Cash 15.69M
Net Cash / Share 0.29
Gross Margin -114.18%
Operating Margin -236.99%
Profit Margin -280.60%
FCF Margin -250.89%
ROA -35.64%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.67*
(264.84% upside)
Low
4.00
Current: $1.28
High
5.00
Target: 4.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue10.0010.439.907.537.889.8415.0016.9714.7616.00
Revenue Growth-4.07%5.35%31.5%-4.46%-19.96%-34.39%-11.61%14.97%-7.73%-
Gross Profit9.509.879.407.137.479.5014.8016.8014.7616.00
Operating Income-24.36-29.33-49.76-58.04-56.48-15.86-9.42-18.62-7.20-5.64
Net Income-32.14-32.58-53.32-60.41-58.98-18.73-12.32-16.42-9.86-4.44
Shares Outstanding33.1833.1229.8326.5624.6717.1916.4715.8115.2714.99
Earnings Per Share-0.97-0.98-1.79-2.25-2.40-1.10-0.75-1.05-0.65-0.30
Operating Cash Flow-26.21-30.07-48.36-35.81-29.89-16.81-9.54-15.19-4.56-1.63
Capital Expenditures-0.04-0.09-0.19-0.33-0.02-0.09-0.15-0.10-0.18-0.18
Free Cash Flow-26.25-30.15-48.54-36.14-29.92-16.90-9.69-15.30-4.75-1.80
Cash & Equivalents20.7024.4260.2344.4982.1949.7658.1955.5537.7240.60
Total Debt0.1735.4841.5619.8624.1728.3030.5629.84--
Net Cash / Debt20.53-11.0618.6824.6358.0321.4727.6425.7137.7240.60
Assets35.1137.3773.8057.7594.9762.6180.5969.7748.1850.65
Liabilities69.0241.8649.8128.4930.4632.8335.4235.508.305.13
Book Value-33.91-4.5023.9929.2764.5129.7845.1734.2739.8845.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Curis, Inc.
Country United States
Employees 28
CEO James E. Dentzer

Stock Information

Ticker Symbol CRIS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRIS
IPO Date August 1, 2000

Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company also has a scientific collaboration with DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments for Fimepinostat in DLBCL and solid malignancies. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.